Palforzia treatment resulted in a significant increase in the amount of peanut protein tolerated
The European Commission (EC) has approved the use of Palforzia for the treatment of peanut allergy in the European Union (EU). Developed by Aimmune Therapeutics, Inc., a Nestlé Health Science Company, Palforzia is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients 18 years and older and must be used in conjunction with a peanut-avoidant diet.
“Today’s news of the EC approval represents the first-ever treatment option approved for peanut allergy in the EU and underscores our vision of providing end-to-end solutions as a driver of wellness and treatment, in the key growth areas of nutrition, metabolism, healthy aging and food allergy,” said Greg Behar, CEO, Nestlé Health Science.
Andrew Oxtoby, President and CEO of Aimmune Therapeutics, said, “Now we turn our efforts toward working with health authorities to ensure access to this first-of-kind treatment for those children with peanut allergy for whom our product is appropriate as we prepare to launch in Germany and the UK in May 2021.”
The approval was based on a package of data, including from two phase-3 clinical trials Palisade and Artemis.5,6,7 In both studies, Palforzia treatment resulted in a significant increase in the amount of peanut protein tolerated, compared to placebo.6,7